Original Contributions |
From the Department of Medicine, University of Würzburg (A.H., S.O.-M., T.R., K.N., K.S., C.B., L.N.); Department of Physiology, University of Bonn (F.G., K.W.L., R.M.); Department of Medicine, Cardiology and Angiology, Medical Faculty, Mannheim, University of Heidelberg (K.H., H.H., P.G., G.E.); Max Delbrück Center for Molecular Medicine, Berlin (S.H., U.G., R.V.); and the Institute of Physiology, University of Leipzig (H.G.Z.), Germany. Present affiliation for A.H. is Developmental Genetics, Max Delbrueck Center for Molecular Medicine, Berlin, Germany. Present affiliation for R.V. is Institute of Clinical Pharmacology and Toxicology, Benjamin Franklin Medical Center, Berlin, Germany. Present affiliation for C.B. is Department of Anesthesiology, University of Würzburg, Germany.
Correspondence to Ludwig Neyses, MD, Department of Medicine, University of Würzburg, Josef-Schneider-Str 2, D-97080 Würzburg, Germany.
| Abstract |
|---|
|
|
|---|
- and ß-adrenergic signal transduction pathways
recently have been localized to caveolae, we tested the hypothesis that
the PMCA might alter the amplitude of
- and ß-adrenergic growth
signals by virtue of its localization in caveolae. Biochemical as well
as immunocytochemical studies suggested that the PMCA in large part was
colocalized with caveolin 3 in caveolae of cardiomyocytes.
These results indicate that the sarcolemmal Ca2+-pump has
little relevance for beat-to-beat regulation of contraction/relaxation
in adult animals but likely plays a role in regulating myocardial
growth, possibly through modulation of caveolar signal
transduction.
Key Words: plasma membrane Ca2+-ATPase myocardium transgenic rat contraction cardiac growth
| Introduction |
|---|
|
|
|---|
In nonexcitable cell types, the PMCA is the only known enzyme-mediating calcium extrusion and therefore has been postulated to have a housekeeping function.19 However, in excitable cells, which express the high capacity Na+/Ca2+ exchanger as an additional sarcolemmal (SL) calcium transporter, the functional importance of the PMCA remains unclear.
In the myocardium, it has been assumed that the PMCA shares the burden of extruding calcium from the cell after each beat with the Na+/Ca+ exchanger. In particular, the high calcium affinity of the PMCA has led to the speculation that it is responsible for fine tuning of calcium in the final phase of diastole.
On the other hand, in isolated adult cardiomyocytes, the sodium/calcium exchanger has been demonstrated to have a much higher calcium transport activity than the PMCA.20 Under the assumption that these in vitro studies are representative of the situation in whole heart, the PMCA may play only a minor role in beat-to-beat regulation of contraction/relaxation.
Recently published results indicate that the PMCA plays a role in growth and differentiation processes. We reported that L6 skeletal myoblasts stably overexpressing the PMCA showed a markedly accelerated myogenic differentiation into myotubes.21 Consistent with these findings, results published by other groups also suggest an active role of the enzyme in growth regulation. Liu and coworkers22 showed a delay in G1-S phase transition in rat aortic endothelial cells overexpressing rat PMCA1a. Husain et al23 demonstrated a significantly slower growth rate in PMCA-overexpressing vascular smooth muscle cells, and Brandt et al24 published results showing an inhibition of nerve growth factorinduced neurite outgrowth in pheochromocytoma cells transfected with a PMCA 1 antisense construct.
To address the unresolved issue of the function of the PMCA in the myocardium, in the present work, we established transgenic rat lines overexpressing the PMCA in the myocardium as a "gain of function" model. This allowed us to address hypotheses directly about the role of this pump in contraction/relaxation and/or cellular growth processes.
| Materials and Methods |
|---|
|
|
|---|
-myosin heavy chain
(
-MHC) promoter.26 The first expression
construct was composed of the 250-bp MLC-2 promoter, a 325-bp simian
virus (SV) 40 intervening sequence (IVS), the 3.6-kb hPMCA4CI
cDNA, a 600-bp SV 40 IVS, and the 240-bp SV 40 poly A signal. The
second expression construct contained the 2.9-kb
-MHC promoter, a
400-bp 5' untranslated region of the
-MHC gene, the 3.6-kb hPMCA4CI
cDNA, the 600-bp SV 40 IVS, and the 240 bp SV 40 poly A signal. The
sequence of both expression constructs was confirmed by restriction
endonuclease digestion and DNA sequencing. The MLC-2 promoter and the
325-bp SV 40 IVS sequence were provided kindly by Dr Kenneth Chien and
Genentech Inc; the
-MHC promoter was a gift from Dr Bruce Markham
(Ann Arbor, Mich). The 3.6-kb hPMCA4CI cDNA was provided kindly by Dr
Emanuel Strehler (Rochester, Minn). The expression constructs were
excised from the vector, gel-purified, and used for pronuclear
microinjection of fertilized oocytes from Sprague-Dawley (SD) rats to
produce transgenic rats according to the procedure described by Mullins
and Ganten.27 Genomic DNA (10 µg) from rat tail
biopsies were subjected to EcoRI digestion and Southern blot
analysis according to the standard procedures using an hPMCA4CI
cDNAspecific 1.2-kb EcoRI fragment (corresponding to
nucleotides 2177 to 3403 of
hPMCA4CI)6 as a probe.
Northern Blot Analysis
Expression of the human PMCA isoform 4 mRNA was detected by
Northern blot analysis of total RNA from transgenic rat hearts.
Twenty micrograms of total RNA was run on a 1% formaldehyde-agarose
gel, and Northern blotting was performed according to standard
procedures. For hybridization, a randomly primed labeled 1200-bp EcoRI
fragment of the human PMCA4CI cDNA was used. Three of the four
established transgenic lines with the MLC-2 promoterdriven transgene
and 1 out of 2 lines with the
-MHC promoter showed mRNA expression
of the PMCA transgene. Expression was most abundant in total heart and
also in isolated cardiomyocytes from adult and neonatal
hearts, but lower expression was also detectable in brain, lung, and
kidney. No expression of the transgene was found in atrium, skeletal
muscle, liver, or noncardiomyocytes from transgenic
neonatal rat hearts.
Western Blot Analysis and Analysis of
Transgene Activity
Preparation of Highly Purified Plasma Membranes From Cardiac
Tissue
Heart tissue (2 g) was frozen in liquid nitrogen and powdered
before homogenization in 20 mL buffer containing
(in mmol/L): histidine 5 (pH 7.7), KCl 750, DTT 0.2, and PMSF 0.1.
The sample was centrifuged at 3000g for 15 minutes,
the pellet was resuspended in 20 mL homogenization
buffer, and the previous step was repeated. The pellet was resuspended
in 20 mL hypotonic medium containing 10 mmol/L
NaHCO3 (pH 7.4), 5 mmol/L histidine, and
0.2 mmol/L DTT, centrifuged at 3000g for 15
minutes, and the pellet was homogenized (3x30 s; 21 000
rpm) in 20 mL hypotonic medium. The homogenate was
centrifuged at 12 400g for 20 minutes, the pellet
was treated identically to the previous step, and the supernatants were
pooled and centrifuged at 45 000g for 30 minutes.
The pellet was resuspended in 1 mL sucrose-histidine buffer I (250
mmol/L sucrose, 10 mmol/L histidine [pH 7.4], 160 mmol/L
KCl) and centrifuged on a sucrose gradient (18% to 35%) for
90 minutes at 100 000g. The SL fraction was harvested, and
3.2 mL of 600 mmol/L KCl was added. The SL preparation was
centrifuged at 60 000 rpm for 20 minutes, and the pellet was
resuspended in sucrose-histidine buffer II (250 mmol/L sucrose,
10 mmol/L histidine [pH 7.4]) and centrifuged as in the
previous step. The final pellet was resuspended in 200 µL
sucrose-histidine buffer II.
Western Blot Analysis
The SL preparations were separated by SDS-PAGE and transferred
to polyvinylidene fluoride membranes.28
Blocking was performed overnight with 1% BSA. The membranes were
incubated for 1 hour with the monoclonal anti-PMCA antibody 5F10
(1:1000 dilution), recognizing all 4 isoforms of the PMCA expressed in
rat and human tissues (Affinity BioReagents, Hamburg, Germany). After a
washing step (1xPBS; pH 7.45; 1% BSA), incubation with the secondary
antibody (a sheep anti-mouse antibody coupled to alkaline phosphatase;
Amersham, Braunschweig, Germany) at a 1/5000 dilution was performed for
1 hour. After a further washing step in 1xPBS (pH 7.45), 1% BSA, and
0.3% Tween, immunocomplexes were visualized by chemoluminescence
according to the manufacturer's protocol (ECL-kit, Amersham). For the
detection of caveolin 3 in Western blotting experiments, a monoclonal
antibody (Transduction Laboratories), recognizing rat and human
caveolin 3, was used as described above.
For quantification, the data were normalized to Na+/Ca2+ exchanger protein (expression of the Na+/Ca2+ exchanger protein was unchanged in the myocardium of transgenic animals as detected by Western blot analysis). Further normalization to cell number and total protein revealed similar results. The polyclonal antibody used to detect the Na+/Ca2+ exchanger was obtained from SWant.
Coupled Enzyme Assay Measuring Ca2+-Dependent
ATPase Activity
The reaction mixture contained 50 nmol/L
CaCl2, 50 mmol/L HEPES-Tris (pH 7.4),
160 mmol/L KCl, 2 mmol/L MgCl2, 5
mmol/L NaN3, 1 µg/mL alamethicin, 1 mmol/L
ATP-Tris, 1 mmol/L phosphoenolpyruvate, 1 U/mL
pyruvatekinase, 0.6 mmol/L NADH, 1 U/mL
lactatedehydrogenase. The reaction was started by adding 10 µg of
highly purified SL protein to 1 mL of the mixture, and the optical
density of NADH/NAD was measured over 2 minutes in a
spectrophotometer at 340 nm at 37°C. To stop the
Ca2+-dependent ATPase activity, 2 mmol/L
EGTA was added, and the measurement was continued for 2 minutes. The
Ca2+-dependent ATPase activity was calculated by
subtracting the 2 fitted slopes.
Measurements of L-Type Ca2+ Current
and Fura-2 Fluorescence Ratios in Isolated Adult
Cardiomyocytes
Isolation of Adult Cardiomyocytes
Adult cardiomyocytes from transgenic and normal SD
rats (female and male; body weight, 230 to 490 g) were isolated by
the method described by Stegemann et al29 for
guinea pig ventricular myocytes with slight modifications
according to Linz and Meyer.30
Measurement of L-Type Ca2+ Current
L-type Ca2+ current was
recorded at 35±1°C using the whole-cell patch-clamp
technique.31 Patch pipettes with tip resistances
of 2 to 4 M
were pulled from borosilicate glass (Hilgenberg) and
connected to a single-electrode continuous-voltage clamp amplifier (L/M
EPC 7, List Medical Electronic). In all measurements, cell capacitance,
series resistance, and junction potentials were compensated.
Voltage-clamp protocols and data acquisition were accomplished using
pClamp 6.0 software (Axon Instruments). Current signals were on-line
filtered at 3 kHz and digitized at 15 kHz by a 12-bit A/D converter
(Digidata 1200, Axon Instruments).
The L-type Ca2+ current was determined as total peak inward current. The separation from overlapping fast Na+ current and T-type Ca2+ current was achieved by holding the cells at -40 mV for the time between the test pulses. K+ currents (IK1, IK, and Ito) were blocked with an external solution containing (in mmol/L): NaCl 115, tetraethylammonium chloride 20, KCl 4, BaCl2 2, MgCl2 1, CaCl2 1.8, 4-aminopyridine 2, HEPES 2, and glucose 11 (pH 7.2) and an electrode-filling solution composed of (in mmol/L): CsCl 130, Mg-ATP 2, and HEPES 10; and 50 µmol/L BAPTA (pH 7.2; Molecular Probes).
To determine current-voltage relations (I/V), steady-state
activation parameters (d
), and
steady-state inactivation parameters
(f
), gapped double-pulse
protocols32 with pulse lengths of 400 ms were
used (stimulation frequency, 0.1 Hz). Current amplitudes were
normalized to the cell capacitance. Fitting of I/V-relations
was performed according to Linz and Meyer.30
Fluorescence Measurement of Fast
[Ca2+]i Transients
Fast [Ca2+]i
transients were elicited by Ca2+ influx through
L-type channels in patch-clamped
cardiomyocytes. In these measurements,
Na+/Ca2+ exchange was
blocked by equimolar substitution of LiCl for
NaCl.33 Lasting voltage-clamp pulses (500 ms;
frequency, 0.2 Hz) were applied from a holding potential of -40 to 20
mV in an external solution containing (in mmol/L): LiCl 135, KCl
4, MgCl2 1, CaCl2 1.8,
4-aminopyridine 2, HEPES 2, and glucose 11 (pH 7.2).
The electrode-filling solution was composed of (in mmol/L): CsCl
130, Mg-ATP 2, HEPES 10, Fura-2/Na+-salt 50
(Molecular Probes); and 1 µmol/L ryanodine; pH 7.2.
[Ca2+]i-transients were
measured at 35±1°C in cells preincubated for 20 minutes in standard
Tyrode's solution (in mmol/L): NaCl 135, KCl 4,
CaCl2 1.8, MgCl2 1, glucose
11, and HEPES 2 (pH 7.2); and 1 g/L BSA containing 5 mmol/L
thapsigargin and 10 µmol/L ryanodine. Fura-2
fluorescence34 was recorded by means
of a fast fluorescence microphotometry system (Zeiss FFP
attached to a Zeiss IM 35 microscope with Zeiss Ultrafluar 100x
objective; Carl Zeiss) synchronized to the patch-clamp setup (dye
loading: 2 µmol/L Fura-2/AM; 20 minutes at 35°C). Fura-2
excitation (340 and 380 nm) was performed with 4-ms time resolution.
Fluorescence emission (420 to 560 nm) of the patch-clamped cell
was recorded by a photomultiplier tube (1.6-mm aperture covering
10 µm in the object plane). Changes in
[Ca2+]i were determined
as relative changes from the calculated ratio, 340:380 nm. The
estimated basal free cytosolic Ca2+ concentration
in myocytes of transgenic and wild-type rats was 90 nmol/L. Absolute
[Ca2+]i was not
determined routinely because of the semiquantitative nature of the
affinity constants used.
Fluorescence Measurement of Slow
[Ca2+]i Transients
Slow [Ca2+]i
transients (range, several minutes) in single
cardiomyocytes were determined by Fura-2/AM
fluorescence measurement using a modification of the PC-based
Hamamatsu ICMS video imaging system (Hamamatsu Photonics KK) described
in detail by Gollnick et al.35 A dual excitation
interference filter wheel (340 and 380 nm) and a 150-W Xenon arc lamp
were used for Fura-2 excitation (0.4-s double flashes) at 5- or 10-s
intervals. Digital intensity images (256x256 pixel; 8-bit resolution;
no image averaging) of emission (425 to 575 nm) were acquired for each
excitation wavelength using a Hamamatsu C2400-77H ICCD camera. Myocytes
were placed in an open plexiglas perfusion chamber (0.2 mL) and adhered
to the laminin-coated glass bottom. Fura-2 fluorescence was
measured in an inverted epifluorescence microscope (Zeiss
Axiovert 100 TV with Zeiss Fluar 40x objective, Carl Zeiss) under
permanent perfusion of buffers at 37±0.5°C. For evaluation of
intensity changes with custom-written software (4 to 5 evaluable
cells/experiment), digital measuring windows were placed within the
cell borders. Background fluorescence was measured separately
for each wavelength and subtracted from each intensity value before the
calculation of 340:380-nm ratio images. Relative ratio changes were not
converted to absolute changes of
[Ca2+]i.
Slow [Ca2+]i transients were elicited by external sodium depletion. After a 25-s baseline interval, standard Tyrode's buffer (see above) was replaced by sodium-free buffer (equimolar substitution of LiCl for NaCl). Fluorescence image acquisition lasted for a total of 17 minutes. Hypercontracting and nonresponding cells were not evaluated. In some experiments, sarcoplasmic reticulum (SR) block was achieved with 30 minutes of preincubation with ryanodine+thapsigargin (10 and 5 µmol/L, respectively). Blocker substances were present throughout the experiment.
Hemodynamic Measurements
For hemodynamic measurements, rats were
anesthetized with ether. Polyethylene cannulas were inserted
into the trachea for artifical ventilation and into the right carotid
artery, right jugular vein, and femoral vein. Pressure was measured
through a short segment of a fluid-filled PE 50 tubing connected to a
microtip manometer (Millar) via a 3-way stopcock, with 0 adjusted to
midchest level. The carotid cannula was advanced briefly into the left
ventricle and then was withdrawn to the aortic arch while pressures
were recorded. The jugular vein cannula was advanced to the right
atrium. Left ventricular systolic and
end-diastolic pressures, the maximum rate of rise in left
ventricular systolic pressure,
dP/dtmax, mean arterial pressure
(MAP), heart rate, and mean right atrial pressure (RAP) were measured
under light ether anesthesia and spontaneous
respiration.
During positive pressure ventilation, and after midsternal thoracotomy, a calibrated flowmeter (2.0 mm; Statham, Inc) was placed around the ascending aorta for continuous measurement of aortic blood flow. Mean aortic blood flow was obtained electronically and taken as cardiac index (CI), as described by Pfeffer et al.36 Systemic vascular resistance index was calculated as (MAP-RAP)/CI and was expressed as mm Hg/mL per min/kg body weight.
After baseline measurements, warmed (39°C to 40°C) Tyrode's solution was infused into the femoral vein at a rate of 40 mL/kg per minute for 45 seconds or until maximal flow was achieved.36 This infusion produces a rise in cardiac output to peak values, followed by a plateau, despite further elevation of RAP. Maximum cardiac performance was defined as peak values of cardiac output and stroke volume during this Tyrode's infusion.
Culture of Neonatal Cardiomyocytes and Protein Synthesis
Measurements
Primary Cell Culture of Neonatal Rat Cardiomyocytes
Cardiomyocytes from 48-hour-old transgenic and normal SD rats
were prepared according to Simpson and Savion37
with minor modifications. The hearts were cut into small pieces and
digested in CBFHH (calcium and bicarbonate free Hanks' with
HEPES) (containing [in mmol/L]: NaCl 137, KCl 5.36,
MgSO4x7 H2O 0.81,
D-glucose 5.55,
KH2PO4 0.44,
Na2HPO4 0.34, HEPES 20.06;
pH 7.4) containing 31 µg/l penicillin G, 10 µg/mL DNase, and 1.5
mg/mL trypsin. FCS was added to the resulting cell suspension to
inactivate trypsin and DNase, and the cells were pelleted
by 10 minutes of centrifugation at 700g and
resuspended in MEM/5 (containing 31 µg/mL penicillin G, 50 µg/mL
streptomycin, 30.74 µg/mL BrdU, 2 µg/mL vitamin
B12, and 5% FCS). Most
noncardiomyocytes were removed by preplating for 1 hour.
After preplating, the supernatant containing >90%
cardiomyocytes was removed, and cells were counted in a
Fuchs-Rosenthal chamber and plated in MEM/5 on 6-well plates at a
density of 0.7 million cells/well (low-density culture).
After 24 hours, the MEM/5 was removed, and the cells were grown for 48 more hours in the serum-free medium MEM/TI (additionally containing 31 µg/mL penicillin G, 50 µg/mL streptomycin, 30.74 µg/mL BrdU, 2 µg/mL vitamin B12, 1 µg/mL transferrin, and 1 µg/mL porcine Zn-insulin). Growth experiments were started on day 3.
Growth Experiments, Measurement of Cellular Protein Synthesis
and Apoptosis Analysis
Primary cell cultures of 48-hour-old transgenic and normal SD
rats were prepared as described above. On day 3, the MEM/TI was
replaced by MEM/TI containing either a growth stimulus, such as 2%
FCS, 20 µmol/L phenylephrine, and 1 µmol/L
isoproterenol, or no stimulus. The cells then were incubated for
several different time periods (6 to 12 to 18 to 24 to 36 hours).
Four hours before the end of the incubation period, medium was changed
into MEM/TI with/without growth stimulus and
3H-Leucine at an activity of 2.5 µCi/mL. After
incubation, the cells were washed 2 times with PBS, lysed with 1% SDS,
and harvested. A small amount of the lysate was used to determine DNA
concentration as a measure of number of cells, using the Hoechst 33258
dye. An equal volume of 10% TCA was added to the lysate. Proteins were
precipitated for 30 minutes at room temperature, pelleted by
centrifugation (10 minutes, 14 000g), and
resuspended in 1% SDS. Radioactivity was measured in a ß-counter.
The CPM:DNA concentration ratio was calculated for each sample, and
changes in protein synthesis by the growth stimuli were depicted as
percentage of the CPM:DNA concentration ratio of the nonstimulated
control cells. Terminal deoxynucleotidyl
transfer-mediated end-labeling of fragmented nuclei (TUNEL
assay)38 was performed on neonatal
cardiomyocytes according to the manufacturer's protocol
(Boehringer Mannheim Biochemicals).
Preparation of Caveolar Membranes
To purify caveolae, we used the protocol described by Song et
al.39 Purified plasma membranes from 5-day-old SD
rats were suspended in MES buffered saline (MBS), disrupted by
sonication and placed at the bottom of a discontinuous 45% to
35%-5% sucrose gradient. After centrifugation at
260 000g for 20 hours, 1-mL fractions were taken starting
from the top, and an equal amount of protein of each fraction was used
in Western blot analysis detecting caveolin 3 (monoclonal
anticaveolin 3 antibody, Transduction Laboratories) and the PMCA (Ab
5F10, Affinity Bioreagents).
Immunostainings and Confocal Microscopy
Primary cell culture of neonatal cardiomyocytes was
performed as described above. Cells were cultured on slides for 48
hours in medium containing 5% FCS and for another 24 hours in
serum-free medium. They were fixed for 30 minutes with 2%
paraformaldehyde at room temperature and then rinsed
twice in PBS. Samples were blocked and permeabilized in
PBS, containing 1% BSA, 0.5% Triton X-100, and 0.1% Tween 20 for 30
minutes at 20°C and then were incubated at 4°C overnight in a
PBS/0.1% BSA solution containing the primary antibodies. For
double-staining, the monoclonal antibody JA3 (a generous gift from Drs
A. Filoteo and J.T. Penniston, Mayo Clinic and Foundation, Rochester,
Minn), generated against the human PMCA isoform 4, and the polyclonal
rabbit anticaveolin 3 antibody (0.25 mg/mL, Transduction
Laboratories) were used. Working dilutions of these antibodies were
1:500. After incubation, the samples were washed 5 times in PBS/0.1%
Tween 20, then in Texas Red-conjugated goat anti-rabbit IgG (1.4
mg/mL), and the Cy2-conjugated goat anti-mouse IgG antibodies (1.3
mg/mL, Jackson ImmunoResearch Laboratories) were applied in PBS (1:500
and 1:250, respectively) for 1 hour at 4°C. After final washing
steps, the samples were mounted in Vectashield mounting medium (Vector)
and analyzed with a BioRad MRC 1024 confocal laser scanning
system using the LaserSharp software. Statistical analysis was
performed using Student t test, and values are expressed as
SEM unless stated otherwise.
| Results |
|---|
|
|
|---|
|
Quantitative Immunoblotting and Measurement of
ATPase Activity in Transgenics and Controls
To determine the levels of transgene overexpression, highly
purified SL protein preparations from the myocardium of
transgenics and controls were subjected to Western blot
analysis. Quantitative immunoblotting revealed
a 2.5-fold PMCA overexpression in transgenic neonatal
cardiomyocytes and 1.6-fold overexpression of the calcium
pump in adult cardiomyocytes compared with controls (Figure 1B
).
To assess the function of the overexpressed PMCA, Ca2+-dependent ATPase activity was measured in highly purified plasma membrane preparations of the myocardium. The Ca2+-dependent ATPase activity in the hearts of adult homozygous rats (line 1142) was 12.6 µmol ADP/mg protein/h compared with a level of 7.1 U in controls. These results fit well with our protein data (see above) and suggest that the transgene was entirely functional.
Expression of Endogenous Calcium-Transporting Systems
in the Heart of hPMCA4CI-Overexpressing Rats
In cardiac tissue from PMCA-transgenic rats, no compensatory up-
or down-regulation of the
Na+/Ca2+ exchanger,
SERCA2a, and endogenous rat PMCA 1 mRNA was detected
(Figure 2
). The transgenics showed the
normal decrease in expression of the
Na+/Ca2+ exchanger and
increase in expression of the SERCA2a and the endogenous
PMCA1 during development from neonatal to adult rats.
|
Furthermore, endogenous MLC-2 expression was not altered in transgenic animals (data not shown). This was excluded, because transgene expression was driven by the MLC-2 promoter; hence, down-regulation of the endogenous promoter activity might occur. This data showed that phenotypic differences between transgenics and controls would be due to transgene overexpression rather than compensatory changes in other Ca2+ transporters.
In Vivo Hemodynamic Experiments
One hypothesis was that the PMCA might play a role in the cardiac
contraction/relaxation cycle. Physiological
measurements assessing the contraction/relaxation
parameters such as left ventricular
systolic pressure, mean aortic pressure,
dP/dtmax, left ventricular
end-diastolic pressure, RAP, and heart rate are summarized
in Tables 1
and 2
. Adult transgenic rats showed no
significant differences in baseline or peak cardiac performance
compared with SD wild-type rats.
|
|
Electrophysiological Studies and Calcium
Measurements
Electrophysiological studies and Fura-2
measurements on isolated adult cardiomyocytes were
performed to determine if the increase in PMCA expression resulted in
corresponding alterations of
electrophysiological parameters
and/or the calcium transient. As shown in Figure 3
, there are no differences in voltage
dependence, activation, and inactivation behavior of L-type
Ca2+ current between transgenic cells and control
adult cardiomyocytes. Furthermore, transgenic and control
cardiomyocytes displayed an identical time course in fast
[Ca2+]i transients
induced by calcium influx through L-type channels in the
presence of thapsigargin and ryanodine (SR block; Figure 4A
). The slow decline of
[Ca2+]i transients after
Na+ depletion was faster slightly but not
significantly in cardiomyocytes isolated from
PMCA-transgenic animals (Figure 4B
), attesting to the activity of the
transgene but suggesting that a decrease in
[Ca2+]i in the
myofilament compartment was not a major effect of transgene
overexpression. When the SR was blocked by thapsigargin and ryanodine,
a marginally different time constant (
) of
[Ca2+]i decline was seen:
=180.5 s (n=14) in controls versus
=214.7 s (n=17) in transgenic
cardiomyocytes (data not shown). The
values of the
monoexponential fit functions are given in the legend
to Figure 4B
. They are given without SD because mean values of an
exponential function constant were fitted. The Fura-2
fluorescence ratios at rest were slightly different: ratio
340:380 nm was 0.89±0.17 (n=14 cells; 4 different animals) in controls
versus 1.14±0.36 nm (n=17 cells; 4 different animals) in transgenic
animals. Although both alterations could be indicative of compensatory
mechanisms, they are so small that their biological relevance is
probably minor.
|
|
Cardiomyocyte Growth
Our second main hypothesis, derived from
our16 21 and others'22 23 24
results, was that the PMCA is involved in long-term cellular processes
such as growth and differentiation rather than in beat-to-beat
regulation of contraction/relaxation. As a model system for cardiac
hypertrophy, we used primary low-density cultures of
neonatal cardiomyocytes as a well-established
model.37 Transgenic compared with wild-type
cardiomyocytes revealed a 1.6- and 2.3-fold higher protein
synthesis rate on stimulation with 2% FCS for 24 hours and 36 hours,
respectively (Figure 5A
). After
incubation with 20 µmol/L phenylephrine,
PMCA-overexpressing cells displayed a 2.0-fold higher level in protein
synthesis (Figure 5B
). Transgenic cardiomyocytes displayed
a 1.4- and 2.0-fold higher peak in growth response on incubation with
1 µmol/L isoproterenol for 12 hours and 24 hours, respectively
(Figure 5C
).
|
Differences in growth were not due to a difference in the viability of
transgenic and wild-type cardiomyocytes, as there were no
significant differences in the number of apoptotic cells in
both cultures (Figure 6
).
Apoptotic cells were detected by the TUNEL assay.
|
Localization of the PMCA in Caveolae
To begin to unravel the mechanisms for the altered growth in
transgenic cardiomyocytes, we tested the hypothesis that
the PMCA is localized to caveolae. In differential density gradient
centrifugation, the PMCA could be detected in the same
membrane fraction as caveolin 3 (Figure 7
). Importantly, this fraction
contained only
3% of total membrane protein but close to 100% of
the PMCA as well as the bulk of caveolin 3 protein. These results
represent strong biochemical evidence for the localization of
the PMCA in caveolae.
|
In addition, confocal microscopy studies demonstrated that the
overexpressed hPMCA4CI (as well as the total PMCA-fraction; Figure 8g
through 8i) and caveolin 3 were
colocalized in cultured cardiac myocytes derived from transgenic
animals (Figure 8
). Small color dots represent caveolae,
whereas larger aggregates likely are Golgi complexes; shuttling of
caveolae between the plasma membrane and the Golgi complex has been
shown repeatedly.40 Interestingly, in analogy to
several other proteins localized to caveolae,40
there seem to be areas of the cell membrane where the PMCA is localized
outside caveolae (Figure 8
; also see Discussion).
|
| Discussion |
|---|
|
|
|---|
It has been discussed whether the PMCA is a calcium pump simply maintaining low cytosolic calcium concentrations and preventing cells from Ca2+ overload or whether it has additional significant physiological roles.40 41 42 In the present work, we have investigated the following 2 hypotheses using transgenic overexpression in the rat heart muscle as a "gain of function" model.
First, we hypothesized that the PMCA might play a role in the cardiac contraction/relaxation cycle. We reasoned that an increased PMCA expression might influence the diastolic Ca2+-decline and hence cardiac relaxation. The second hypothesisbased on previous datatentatively assigned the pump a potential role in regulation of long-term cellular processes in muscle cells, eg growth and differentiation.
The data presented here support an affirmation of the second
hypothesis, whereas the first is made unlikely. With regard to the role
of the PMCA and other Ca2+-transporting enzymes
such as the sarcoplasmic reticulum
Ca2+-ATPase43 44 and the
Na+/Ca2+
exchanger45 46 in the cardiac
contraction/relaxation cycle, most studies have investigated calcium
transients and concomitant contractions of isolated cardiac myocytes.
On the basis of these data, it has been calculated that in the rat
heart, at each beat, only 1% to 2% of
[Ca2+]i decline during
relaxation is mediated by the PMCA and the mitochondrial
Ca2+-uniporter together, whereas
Na2+/Ca2+ exchange across
the plasma membrane accounts for
25% of calcium removal; the
sarcoplasmic reticulum pump is responsible for pumping the bulk flow of
calcium (
75%) out of the myofilament
compartment.47
These data have been disputed on the grounds that the use of isolated cells in these experiments may not be representative of the situation in the intact myocardium. Furthermore, the sequential use of inhibitors of the various calcium transporters may have interfered with other cellular functions, and no specific inhibitor of the PMCA is available.
In our transgenic "gain of function" model, overexpression and activity of the transgene were ascertained, and compensatory changes in the expression level of major endogenous genes involved in cardiac calcium handling because of the PMCA overexpression were excluded. Thus, we believe that differences in phenotype between transgenics and controls were due to overexpression of the transgene rather than to compensatory changes in other Ca2+ transporters.
Functional alterations that may result from increased PMCA expression first were investigated by in vivo hemodynamic measurements in adult transgenic rats and by determining calcium transients in isolated adult cardiomyocytes. Hemodynamic parameters reflecting the contractility of the adult myocardium and pertinent fast calcium transients, as well as a variety of other pivotal components of electromechanical coupling, were unchanged.
In this context, it is interesting to note that overexpression of the
SERCA2 (
20%) in transgenic mice indeed could induce a significantly
faster decline of the calcium transient and resulted in enhanced
cardiac contractility.48
Furthermore, transgenic mice overexpressing wild-type or a mutant form
of phospholamban, the regulator of the cardiac SERCA, to approximately
the same extent in the myocardium as in our animals showed
alterations in contractile parameters predicted by in vitro
and single cell experiments.49 50 Overexpressing
the Na+/Ca2+ exchanger in
the myocardium of transgenic mice did not significantly
alter the resting calcium concentration, the magnitude of triggered
Ca2+i-transients, or the
Ca2+ current density but did accelerate the rate
of removal of Ca2+ from the cytosol, when SR
uptake was impaired by caffeine.51
Because in our animals, overexpression of the PMCA was at least as high or higher than the overexpression of these other proteins, which did lead to alterations in contractility, we conclude that the PMCA has little, if any, role in the beat-to-beat regulation of the contraction/relaxation cycle.
The second hypothesis tested in the present work tentatively assigned the PMCA a role in growth regulation. This concept was based on our previous results, showing a dramatic effect of PMCA overexpression on the differentiation of skeletal muscle cells21 and on results reported by others demonstrating an influence of PMCA overexpression on cellular growth.22 23 52 53 Furthermore, inhibition of the PMCA using the antisense approach showed an influence of the pump on differentiation of pheochromocytoma cells.24
Therefore, we focused our analysis on the growth of neonatal cardiomyocytes in culture, which is an established model for the analysis of hypertrophic growth.37 There was a significant difference in the response of transgenic and wild-type cardiac muscle cells to a variety of stimuli. PMCA overexpressing cells on average showed a 2-fold higher protein synthesis rate compared with controls.
These differences were not due to a difference in the viability of transgenic cardiomyocytes, as the percentage of apoptotic cells was similar. Whereas neonatal PMCA overexpressing cardiomyocytes showed an increased growth, the adult myocardium of transgenic rats did not display signs of hypertrophy. This could be because of compensatory mechanisms (frequently seen in transgenic animals) preventing hypertrophy in the adult heart at least under normal conditions. The effect of PMCA overexpression under pathological conditions awaits further testing.
Dissecting the mechanisms responsible for the alteration in growth was not the immediate goal of the present work, but as a step toward creating testable hypotheses, we investigated whether the PMCA is localized in caveolae of rat cardiomyocytes. Previously, there had been preliminary indications that the PMCA is localized in caveolae: Fujimoto54 published results based on immunogold labeling of the PMCA, showing the presence of the calcium pump in caveolae of various mouse tissues, but only tentatively in the myocardium. Schnitzer et al55 reported the presence of the PMCA in purified caveolar fractions of rat lung endothelial cells. For the first time, our results present biochemical evidence for localization of the PMCA in caveolae of the myocardium and show colocalization of the PMCA and caveolin 3 based on double-immunostaining. Caveolin 3, but not caveolin 1 or 2, is expressed in the myocardium.40 It is of interest that our immunofluorescence studies show that there may be compartments of the cell where the PMCA is not colocalized with caveolin, a phenomenon well known for other proteins.40 One possible interpretation is that there may be areas of the cell membrane ("cholesterol-sphingolipid rafts") that fulfill specialized functions in signal transduction in the absence of caveolin.56 This possibility currently is under investigation in our laboratory.
Caveolae (which are abundant in striated muscle) have been implicated
in signal transduction.40 57 Several proteins
recently have been localized to caveolae. Among these are important
signaling molecules such as Gs
, nitric oxide synthase, ras,
src-tyrosine kinase, and channels such as the IP3-sensitive
Ca2+ channel.40 In view of
our results and these recent findings about caveolae, we hypothesize
that the calcium pump modulates the amplitude of signaling through
molecules targeted to caveolae either by direct interaction and/or a
modification of subcellular Ca2+
pools.58 59 60 It is not yet technically possible
to measure calcium directly in 50- to 100-nm structures. Therefore,
indirect methods will have to be used to address the latter
question.
In conclusion, the data presented in this paper strongly suggest that future concepts about the function of the PMCA in the myocardium (and possibly in other tissues) should include a role for PMCA in long-term cellular processes such as growth and caveolar signal transduction. The assumption of participation of the pump in the contraction/relaxation cycle, as well as the hypothesis that the PMCA represents a mere "evolutionary remnant" in the myocardium, are both made unlikely by our data.
| Acknowledgments |
|---|
Received December 9, 1997; accepted July 1, 1998.
| References |
|---|
|
|
|---|
2.
Shull GE, Greeb J. Molecular cloning of two isoforms
of the plasma membrane Ca2+-transporting ATPase
from rat brain. J Biol Chem. 1988;263:86468650.
3. Strehler EE. Plasma membrane Ca2+ pumps and Na+/Ca2+ exchangers. Semin Cell Biol. 1990;1:283295.[Medline] [Order article via Infotrieve]
4.
Carafoli E. The Ca2+-pump of the
plasma membrane. J Biol Chem. 1992;267:21152118.
5.
Verma AK, Filoteo AG, Stanford DR, Wieben ED,
Penniston JT, Strehler EE, Fischer R, Heim R, Vogel G, Mathews S, Page
MA, James P, Vorherr T, Krebs J, Carafoli E. Complete primary structure
of a human plasma membrane Ca2+ pump.
J Biol Chem. 1988;263:1415214159.
6.
Strehler EE, James P, Fischer R, Heim R, Vorherr T,
Filoteo AG, Penniston JT, Carafoli E. Peptide sequence analysis
and molecular cloning reveal two calcium pump isoforms in the human
erythrocyte membrane. J Biol Chem. 1990;265:28352842.
7.
Heim R, Iwata T, Zvaritch E, Adamo HP, Rutishauser B,
Strehler EE, Guerini D, Carafoli E. Expression, purification, and
properties of the plasma membrane Ca2+ pump and
of its N-terminally truncated 105-kDa fragment. J Biol
Chem. 1992;267:2447624484.
8. Brown BJ, Hilfiker H, De Marco SJ, Zacharias DA, Greenwood TM, Guerini D, Strehler EE. Primary structure of human plasma membrane Ca2+-ATPase isoform 3. Biochim Biophys Acta. 1996;1283:1013.[Medline] [Order article via Infotrieve]
9.
Greeb J, Shull GE. Molecular cloning of a third
isoform of the calmodulin-sensitive plasma membrane
Ca2+-transporting ATPase that is expressed
predominantly in brain and skeletal muscle. J Biol
Chem. 1989;264:1856918576.
10. Keeton TP, Shull GE. Primary structure of the rat plasma membrane Ca2+-ATPase isoform 4 and analysis of alternative splicing patterns at splice site A. Biochem J.. 1995;306:779785.
11.
Brandt P, Neve RL, Kammesheidt A, Rhodas RE, Vanaman
TC. Analysis of the tissue-specific distribution of mRNAs
encoding the plasma membrane calcium-pumping ATPases and
characterization of an alternatively spliced form of PMCA 4 at the cDNA
and genomic level. J Biol Chem. 1992;267:43764385.
12.
Keeton TP, Burk SE, Shull GE. Alternative splicing of
exons encoding the calmodulin-binding domains and the C
termini of plasma membrane Ca2+-ATPase isoforms
1, 2, 3, and 4. J Biol Chem. 1993;268:27402748.
13.
Stauffer TP, Hilfiker H, Carafoli E, Strehler EE.
Quantitative analysis of the alternative splicing options of
the human plasma membrane calcium pumps. J Biol Chem. 1993;268:2599326003.
14.
Stauffer TP, Guerini D, Carafoli E. Tissue distribution
of the four gene products of the plasma membrane
Ca2+ pump. J Biol Chem. 1995;270:1218412190.
15. Brandt P, Vanaman TC. Splicing of the muscle-specific plasma membrane Ca2+-ATPase isoform PMCA1c is associated with cell fusion in C2 myocytes. J Neurochem. 1994;62:799802.[Medline] [Order article via Infotrieve]
16. Hammes A, Oberdorf S, Strehler EE, Stauffer T, Carafoli E, Vetter H, Neyses L. Differentiation-specific isoform mRNA expression of the calmodulin-dependent plasma membrane Ca2+-ATPase. FASEB J. 1994;8:428435.[Abstract]
17.
Toescu EC, Petersen OH. Region-specific activity of the
plasma membrane Ca2+-pump and delayed activation
of Ca2+ entry characterize the polarized,
agonist-evoked Ca2+ signal in exocrine
cells. J Biol Chem. 1995;270:85288535.
18.
Neyses L, Reinlib L, Carafoli E.
Phosphorylation of the
Ca2+-pumping ATPase of heart sarcolemma and
erythrocyte plasma membrane. J Biol Chem. 1985;260:1028310287.
19. Carafoli E, Stauffer T. The plasma membrane calcium pump: functional domains, regulation of activity, and tissue specificity of isoform expression. J Neurobiol. 1994;25:312324.[Medline] [Order article via Infotrieve]
20.
Bers DM, Bassani JWM, Bassani RA. Competition and
redistribution among calcium transport systems in rabbit cardiac
myocytes. Cardiovasc Res. 1993;27:17721777.
21.
Hammes A, Oberdorf-Maass S, Jenatschke S, Pelzer T,
Maass A, Gollnick F, Meyer R, Afflerbach J, Neyses L. Expression of the
plasma membrane Ca2+-ATPase in myogenic cells.
J Biol Chem. 1996;271:3081630822.
22. Liu BF, Guangmao C, Kuo TH. Suppression of rat aortic endothelial cell growth by overexpression of plasma membrane calcium pump. Mol Biol Cell. 1995;6:14a. Abstract.
23.
Husain M, See V, Jiang L, See V, Bein K, Simons M,
Alper S, Rosenberg RD. Regulation of vascular smooth muscle cell
proliferation by plasma membrane Ca2+-ATPase.
Am J Physiol. 1997;272:C1947C1959.
24.
Brandt PC, Sisken JE, Neve R, Vanaman TC. Blockade of
plasma membrane calcium pumping ATPase isoform 1 impairs nerve growth
factor-induced neurite extension in pheochromocytoma cells. Proc
Natl Acad Sci U S A. 1996;93:1384313848.
25.
Henderson SA, Spencer M, Sen A, Kumar C, Siddiqui MAQ,
Chien K. Structure, organization, and expression of the rat cardiac
myosin light chain-2 gene: identification of a 250-base pair fragment
which confers cardiac-specific expression. J Biol Chem. 1989;264:1814218148.
26.
Gustafson TA, Markham BE, Bahl JJ, Morkin E. Thyroid
hormone regulates expression of a transfected alpha-myosin heavy-chain
fusion gene in fetal heart cells. Proc Natl Acad Sci
U S A. 1987;84:31223126.
27. Mullins JJ, Ganten D. Transgenic animals: new approaches to hypertension research. J Hypertens. 1990;8:3537.
28. Tobwin H, Staehlin T, Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets. Proc Natl Acad Sci U S A. 1970;76:43504354.
29. Stegemann M, Meyer R, Haas HG, Robert-Nicoud M. The cell surface of isolated cardiac myocytes: a light microscope study with use of fluorochrome-coupled lectins. J Mol Cell Cardiol. 1990;22:787803.[Medline] [Order article via Infotrieve]
30.
Linz KW, Meyer R. Modulation of L-type
calcium current by internal potassium in guinea pig
ventricular myocytes. Cardiovasc Res. 1997;33:110122.
31. Hamill OP, Marty A, Neher E, Sakmann B, Sigworth FJ. Improved patch-clamp techniques for high-resolution current recording from cells and cell-free membrane patches. Pflugers Arch. 1981;391:85100.[Medline] [Order article via Infotrieve]
32.
Eckert R, Tillotson DL. Calcium-mediated inactivation
of the calcium conductance in cesium-loaded giant neurons of
Aplysia californica. J Physiol Lond. 1981;314:265280.
33.
Levesque PC, Leblanc N, Hume JR. Release of calcium
from guinea pig cardiac sarcoplasmatic reticulum induced by
sodium-calcium exchange. Cardiovasc Res. 1994;28:370378.
34.
Grynkiewicz G, Poenie M, Tsien RY. A new generation of
Ca2+ indicators with greatly improved
fluorescence properties. J Biol Chem. 1985;260:34403450.
35. Gollnick F, Meyer R, Stockem W. Visualization and measurement of calcium transients in Amoeba proteus by fura-2 fluorescence. Eur J Cell Biol. 1991;55:262271.[Medline] [Order article via Infotrieve]
36.
Pfeffer JM, Pfeffer MA, Braunwald E. Influence of
chronic captopril therapy on the infarcted left ventricle of the rat.
Circ Res.. 1985;57:8495.
37.
Simpson P, Savion S. Differentiation of rat
cardiomyocytes in single cell cultures with and without
proliferating nonmyocardial cells. Circ Res.. 1982;50:101116.
38.
Gariveli Y, Sherman Y, Ben-Sasson SA. Identification of
programmed cell death in situ via specific labeling of nuclear DNA
fragmentation. J Cell Biol. 1992;119:493501.
39.
Song KS, Li S, Okamoto T, Quilliam LA, Sargiacomo M,
Lisanti MP. Co-purification and direct interaction of ras with
caveolin, an integral membrane protein of caveolae microdomains.
J Biol Chem. 1996;271:96909697.
40. Couet J, Li S, Okamoto T, Scherer PE, Lisanti M. Molecular and cellular biology of caveolae: paradoxes and plasticities. Trends Cardiovasc Med. 1997;7:103110.
41. Monteith GR, Roufogalis BD. The plasma membrane calcium pump: a physiological perspective on its regulation. Cell Calcium. 1995;18:459470.[Medline] [Order article via Infotrieve]
42.
Brandt PC, Vanaman TC. The plasma membrane calcium
pump: not just a another pretty ion translocase.
Glycobiology. 1996;6:665668.
43. Mac Lennan DH, Brandt CJ, Korczak B, Greene NM. Amino acid sequence of a Ca2+ + Mg2+-dependent ATPase from rabbit muscle sarcoplasmic reticulum, deduced from its complementary DNA sequence. Nature. 1985;316:696700.[Medline] [Order article via Infotrieve]
44.
Arai M, Matsui H, Periasamy M. Sarcoplasmic gene
expression in cardiac hypertrophy and heart failure.
Circ Res.. 1994;74:555564.
45.
Caroni P, Reinlib L, Carafoli E. Charge movements
during the
Na+-Ca2+-exchange in heart
sarcolemmal vesicles. Proc Natl Acad Sci U S A. 1980;77:63546358.
46.
Nicoll DA, Longoni S, Philipson KD. Molecular cloning
and functional expression of the cardiac sarcolemmal
Na+-Ca2+ exchanger.
Science. 1990;250:562565.
47.
Bassani JWM, Bassani RA, Bers DM. Relaxation in rabbit
and rat cardiac cells: species-dependent differences in cellular
mechanisms. J Physiol. 1994;476:279293.
48. He H, Giordano FJ, Hilal-Dandan R, Choi DJ, Rockman HA, Mc Donough PM, Bluhm W, Meyer M, Sayen MR, Swanson E, Dillmann WH. Overexpression of the rat sarcoplasmic reticulum Ca2+-ATPase gene in the heart of transgenic mice accelerates calcium transients and cardiac relaxation. J Clin Invest. 1997;100:380389.[Medline] [Order article via Infotrieve]
49. Kadambi VJ, Ponniah S, Harrer JM, Hoit BD, Dorn GW, Walsh RA, Kranias EG. Cardiac-specific overexpression of phospholamban alters calcium kinetics and resultant cardiomyocyte mechanics in transgenic mice. J Clin Invest. 1996;97:533539.[Medline] [Order article via Infotrieve]
50.
Chu G, Dorn GW, Luo W, Harrer JM, Kadambi VJ, Walsh RA,
Kranias EG. Monomeric phospholamban overexpression in transgenic mouse
hearts. Circ Res.. 1997;81:485492.
51.
Adachi-Akahane S, Lu L, Li Z, Frank JS, Philipson KD,
Morad M. Calcium signaling in transgenic mice overexpressing cardiac
Na+-Ca2+ exchanger.
J Gen Physiol. 1997;109:717729.
52.
Guerini D, Schröder S, Foletti D, Carafoli E.
Isolation and characterization of a stable Chinese hamster ovary cell
line overexpressing the plasma membrane
Ca2+-ATPase. J Biol Chem. 1995;270:1464314650.
53.
Liu BF, Xu X, Fridman R, Muallem S, Kuo TH.
Consequences of functional expression of the plasma membrane
Ca2+ pump isoform 1a. J Biol
Chem. 1996;271:55365544.
54.
Fujimoto T. The calcium pump of the plasma membrane is
localized in caveolae. J Cell Biol. 1993;120:11471157.
55.
Schnitzer JE, Oh P, Jacobsen BS, Dvorak AM. Caveolae
from luminal plasmalemma of rat lung
endothelium: microdomains enriched in caveolin,
Ca2+-ATPase, and inositol trisphosphate receptor.
Proc Natl Acad Sci U S A. 1995;92:17591763.
56. Harder T, Simons K. Caveolae, DIGS, and the dynamics of sphingolipid-cholesterol microdomains. Curr Opin Cell Biol. 1997;9:534542.[Medline] [Order article via Infotrieve]
57.
Anderson RGW. Caveolae: where incoming and outgoing
messengers meet. Proc Natl Acad Sci U S A. 1993;90:1090910913.
58. Bootman MD, Berridge MJ. The elemental principles of calcium signaling. Cell. 1995;83:675678.[Medline] [Order article via Infotrieve]
59. Clapham DE. Calcium signaling. Cell. 1995;80:259268.[Medline] [Order article via Infotrieve]
60. Berridge MJ. The AM and FM of calcium signaling. Nature. 1997;386:759760.[Medline] [Order article via Infotrieve]
61. Borke JL, Minami J, Verma A, Penniston JT, Kumar R. Monoclonal antibodies to human erythrocyte membrane Ca++-Mg++ adenosine triphosphate pump recognize an epitope in the basolateral membrane of human kidney distal tubule cells. J Clin Invest. 1987;80:12251231.
62. Caride AJ, Filoteo AG, Enyedi A, Verma AK, Penniston JT. Detection of isoform 4 of the plasma membrane calcium pump in human tissues by using isoform-specific monoclonal antibodies. Biochem J.. 1996;316:353359.
63.
Filoteo AG, Elwess NL, Enyedi A, Caride A, Aung
HH, Penniston JT. Plasma membrane Ca2+ pump in
rat brain. J Biol Chem. 1997;272:2374123747.
This article has been cited by other articles:
![]() |
M. Brini and E. Carafoli Calcium Pumps in Health and Disease Physiol Rev, October 1, 2009; 89(4): 1341 - 1378. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. M. A. Mohamed, D. Oceandy, S. Prehar, N. Alatwi, Z. Hegab, F. M. Baudoin, A. Pickard, A. O. Zaki, R. Nadif, E. J. Cartwright, et al. Specific Role of Neuronal Nitric-oxide Synthase when Tethered to the Plasma Membrane Calcium Pump in Regulating the {beta}-Adrenergic Signal in the Myocardium J. Biol. Chem., May 1, 2009; 284(18): 12091 - 12098. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Oceandy, E. J. Cartwright, M. Emerson, S. Prehar, F. M. Baudoin, M. Zi, N. Alatwi, L. Venetucci, K. Schuh, J. C. Williams, et al. Neuronal Nitric Oxide Synthase Signaling in the Heart Is Regulated by the Sarcolemmal Calcium Pump 4b Circulation, January 30, 2007; 115(4): 483 - 492. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. C. Williams, A. L. Armesilla, T. M. A. Mohamed, C. L. Hagarty, F. H. McIntyre, S. Schomburg, A. O. Zaki, D. Oceandy, E. J. Cartwright, M. H. Buch, et al. The Sarcolemmal Calcium Pump, {alpha}-1 Syntrophin, and Neuronal Nitric-oxide Synthase Are Parts of a Macromolecular Protein Complex J. Biol. Chem., August 18, 2006; 281(33): 23341 - 23348. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. C. Balijepalli, J. D. Foell, D. D. Hall, J. W. Hell, and T. J. Kamp From the Cover: Localization of cardiac L-type Ca2+ channels to a caveolar macromolecular signaling complex is required for beta2-adrenergic regulation PNAS, May 9, 2006; 103(19): 7500 - 7505. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Burkard, J. Becher, C. Heindl, L. Neyses, K. Schuh, and O. Ritter Targeted Proteolysis Sustains Calcineurin Activation Circulation, March 1, 2005; 111(8): 1045 - 1053. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Wernicke, C. Thiel, C. M. Duja-Isac, K. V. Essin, M. Spindler, D. J. R. Nunez, R. Plehm, N. Wessel, A. Hammes, R.-J. Edwards, et al. {alpha}-Tropomyosin mutations Asp175Asn and Glu180Gly affect cardiac function in transgenic rats in different ways Am J Physiol Regulatory Integrative Comp Physiol, September 1, 2004; 287(3): R685 - R695. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. L. Armesilla, J. C. Williams, M. H. Buch, A. Pickard, M. Emerson, E. J. Cartwright, D. Oceandy, M. D. Vos, S. Gillies, G. J. Clark, et al. Novel Functional Interaction between the Plasma Membrane Ca2+ Pump 4b and the Proapoptotic Tumor Suppressor Ras-associated Factor 1 (RASSF1) J. Biol. Chem., July 23, 2004; 279(30): 31318 - 31328. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Brede, W. Roell, O. Ritter, F. Wiesmann, R. Jahns, A. Haase, B. K. Fleischmann, and L. Hein Cardiac Hypertrophy Is Associated With Decreased eNOS Expression in Angiotensin AT2 Receptor-Deficient Mice Hypertension, December 1, 2003; 42(6): 1177 - 1182. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Schuh, T. Quaschning, S. Knauer, K. Hu, S. Kocak, N. Roethlein, and L. Neyses Regulation of Vascular Tone in Animals Overexpressing the Sarcolemmal Calcium Pump J. Biol. Chem., October 17, 2003; 278(42): 41246 - 41252. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Gros, T. Afroze, X.-M. You, G. Kabir, R. Van Wert, W. Kalair, A. E. Hoque, I. N. Mungrue, and M. Husain Plasma Membrane Calcium ATPase Overexpression in Arterial Smooth Muscle Increases Vasomotor Responsiveness and Blood Pressure Circ. Res., October 3, 2003; 93(7): 614 - 621. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. BORLAK and T. THUM Hallmarks of ion channel gene expression in end-stage heart failure FASEB J, September 1, 2003; 17(12): 1592 - 1608. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Schuh, S. Uldrijan, S. Gambaryan, N. Roethlein, and L. Neyses Interaction of the Plasma Membrane Ca2+ Pump 4b/CI with the Ca2+/Calmodulin-dependent Membrane-associated Kinase CASK J. Biol. Chem., March 7, 2003; 278(11): 9778 - 9783. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Ratajczak, T. Damy, C. Heymes, P. Oliviero, F. Marotte, E. Robidel, R. Sercombe, J. Boczkowski, L. Rappaport, and J.-L. Samuel Caveolin-1 and -3 dissociations from caveolae to cytosol in the heart during aging and after myocardial infarction in rat Cardiovasc Res, February 1, 2003; 57(2): 358 - 369. [Abstract] [Full Text] [PDF] |
||||
![]() |
O. Ritter, S. Hack, K. Schuh, N. Rothlein, A. Perrot, K. J. Osterziel, H. D. Schulte, and L. Neyses Calcineurin in Human Heart Hypertrophy Circulation, May 14, 2002; 105(19): 2265 - 2269. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Piuhola, A. Hammes, K. Schuh, L. Neyses, O. Vuolteenaho, and H. Ruskoaho Overexpression of sarcolemmal calcium pump attenuates induction of cardiac gene expression in response to ET-1 Am J Physiol Regulatory Integrative Comp Physiol, September 1, 2001; 281(3): R699 - R705. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. N. Muth, I. Bodi, W. Lewis, G. Varadi, and A. Schwartz A Ca2+-Dependent Transgenic Model of Cardiac Hypertrophy : A Role for Protein Kinase C{{alpha}} Circulation, January 2, 2001; 103(1): 140 - 147. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. E. Strehler and D. A. Zacharias Role of Alternative Splicing in Generating Isoform Diversity Among Plasma Membrane Calcium Pumps Physiol Rev, January 1, 2001; 81(1): 21 - 50. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Hattori, N. Matsuda, J. Kimura, T. Ishitani, A. Tamada, S. Gando, O. Kemmotsu, and M. Kanno Diminished function and expression of the cardiac Na+-Ca2+ exchanger in diabetic rats: implication in Ca2+ overload J. Physiol., August 15, 2000; 527(1): 85 - 94. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. O. Rybin, X. Xu, and S. F. Steinberg Activated Protein Kinase C Isoforms Target to Cardiomyocyte Caveolae : Stimulation of Local Protein Phosphorylation Circ. Res., May 14, 1999; 84(9): 980 - 988. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Hasenfuss Calcium Pump Overexpression and Myocardial Function : Implications for Gene Therapy of Myocardial Failure Circ. Res., November 2, 1998; 83(9): 966 - 968. [Full Text] [PDF] |
||||
![]() |
T. de Jager, T. Pelzer, S. Muller-Botz, A. Imam, J. Muck, and L. Neyses Mechanisms of Estrogen Receptor Action in the Myocardium. RAPID GENE ACTIVATION VIA THE ERK1/2 PATHWAY AND SERUM RESPONSE ELEMENTS J. Biol. Chem., July 20, 2001; 276(30): 27873 - 27880. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Schuh, S. Uldrijan, M. Telkamp, N. Rothlein, and L. Neyses The plasmamembrane calmodulin-dependent calcium pump: a major regulator of nitric oxide synthase I J. Cell Biol., October 15, 2001; 155(2): 201 - 206. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Circulation Research Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 1998 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |